@article{MTMT:34596173,
	title = {Plasma steroid concentrations reflect acute disease severity and normalise during recovery in people hospitalised with COVID-19},
	url = {https://m2.mtmt.hu/api/publication/34596173},
	author = {Devine, Kerri and Russell, Clark D. and Blanco, Giovanny R. and Walker, Brian R. and Homer, Natalie Z. M. and Denham, Scott G. and Simpson, Joanna P. and Leavy, Olivia C. and Elneima, Omer and McAuley, Hamish J. C. and Shikotra, Aarti and Singapuri, Amisha and Sereno, Marco and Saunders, Ruth M. and Harris, Victoria C. and Houchen-Wolloff, Linzy and Greening, Neil J. and Lone, Nazir I. and Thorpe, Mathew and Greenhalf, William and Chalmers, James D. and Ho, Ling-Pei and Horsley, Alex and Marks, Michael and Raman, Betty and Moore, Shona C. and Dunning, Jake and Semple, Malcolm G. and Andrew, Ruth and Wain, Louise V. and Evans, Rachael A. and Brightling, Christopher E. and Baillie, John Kenneth and Reynolds, Rebecca M.},
	doi = {10.1111/cen.15012},
	journal-iso = {CLIN ENDOCRINOL},
	journal = {CLINICAL ENDOCRINOLOGY},
	unique-id = {34596173},
	issn = {0300-0664},
	abstract = {ObjectiveEndocrine systems are disrupted in acute illness, and symptoms reported following coronavirus disease 2019 (COVID-19) are similar to those found with clinical hormone deficiencies. We hypothesised that people with severe acute COVID-19 and with post-COVID symptoms have glucocorticoid and sex hormone deficiencies.Design/PatientsSamples were obtained for analysis from two UK multicentre cohorts during hospitalisation with COVID-19 (International Severe Acute Respiratory Infection Consortium/World Health Organisation [WHO] Clinical Characterization Protocol for Severe Emerging Infections in the UK study), and at follow-up 5 months after hospitalisation (Post-hospitalisation COVID-19 study).MeasurementsPlasma steroids were quantified by liquid chromatography-mass spectrometry. Steroid concentrations were compared against disease severity (WHO ordinal scale) and validated symptom scores. Data are presented as geometric mean (SD).ResultsIn the acute cohort (n = 239, 66.5% male), plasma cortisol concentration increased with disease severity (cortisol 753.3 [1.6] vs. 429.2 [1.7] nmol/L in fatal vs. least severe, p < .001). In males, testosterone concentrations decreased with severity (testosterone 1.2 [2.2] vs. 6.9 [1.9] nmol/L in fatal vs. least severe, p < .001). In the follow-up cohort (n = 198, 62.1% male, 68.9% ongoing symptoms, 165 [121-192] days postdischarge), plasma cortisol concentrations (275.6 [1.5] nmol/L) did not differ with in-hospital severity, perception of recovery, or patient-reported symptoms. Male testosterone concentrations (12.6 [1.5] nmol/L) were not related to in-hospital severity, perception of recovery or symptom scores.ConclusionsCirculating glucocorticoids in patients hospitalised with COVID-19 reflect acute illness, with a marked rise in cortisol and fall in male testosterone. These findings are not observed 5 months from discharge. The lack of association between hormone concentrations and common post-COVID symptoms suggests steroid insufficiency does not play a causal role in this condition.},
	keywords = {CORTISOL; testosterone; Adrenal; COVID 19; Long COVID},
	year = {2024},
	eissn = {1365-2265},
	orcid-numbers = {Marks, Michael/0000-0002-7585-4743; Andrew, Ruth/0000-0002-6916-2994}
}

@article{MTMT:34617282,
	title = {Effects of different insulin sensitisers in the management of polycystic ovary syndrome: A systematic review and meta-analysis},
	url = {https://m2.mtmt.hu/api/publication/34617282},
	author = {Melin, Johanna M. and Forslund, Maria and Alesi, Simon J. and Piltonen, Terhi and Romualdi, Daniela and Spritzer, Poli M. and Tay, Chau Thien and Pena, Alexia S. and Witchel, Selma F. and Mousa, Aya and Teede, Helena J.},
	doi = {10.1111/cen.14983},
	journal-iso = {CLIN ENDOCRINOL},
	journal = {CLINICAL ENDOCRINOLOGY},
	volume = {100},
	unique-id = {34617282},
	issn = {0300-0664},
	abstract = {ObjectiveCharacteristic features of polycystic ovary syndrome (PCOS) include insulin resistance and an increased risk for type 2 diabetes. To promote improved insulin sensitivity, insulin sensitisers have been used in PCOS. However, direct comparisons across these agents are limited. This study compared the effects of metformin, rosiglitazone and pioglitazone in the management of PCOS to inform the 2023 International Evidence-based PCOS Guideline.DesignSystematic review and meta-analysis of the literature.PatientsWomen with PCOS and treatment with insulin sensitisers.MeasurementsHormonal and clinical outcomes, as well as side effects.ResultsOf 1660 publications identified, 13 randomised controlled trials were included. Metformin was superior in lowering weight (mean difference [MD]: -4.39, 95% confidence interval [CI]: -7.69 to -1.08 kg), body mass index (MD: -0.95, 95% CI: -1.41 to -0.49 kg/m2) and testosterone (MD: -0.10, 95% CI: -0.18 to -0.03 nmol/L) versus rosiglitazone, whereas there was no difference when comparing metformin to pioglitazone. Adding rosiglitazone or pioglitazone to metformin did not improve metabolic outcomes. However, rosiglitazone seemed superior to metformin in lowering lipid concentrations.ConclusionsMetformin should remain the first-line insulin sensitising treatment in adults with PCOS for the prevention and management of weight and metabolic features. The addition of thiazolidinediones appears to offer little benefit.},
	keywords = {Insulin Resistance; metformin; rosiglitazone; pioglitazone; Polycystic Ovary Syndrome; BMI; Thiazolidinediones},
	year = {2024},
	eissn = {1365-2265},
	pages = {149-163},
	orcid-numbers = {Forslund, Maria/0000-0002-6674-3849}
}

@article{MTMT:34593007,
	title = {Management aspects of congenital adrenal hyperplasia during adolescence and transition to adult care},
	url = {https://m2.mtmt.hu/api/publication/34593007},
	author = {Balagamage, Chamila and Arshad, Amynta and Elhassan, Yasir S. and Ben Said, Wogud and Krone, Ruth E. and Gleeson, Helena and Idkowiak, Jan},
	doi = {10.1111/cen.14992},
	journal-iso = {CLIN ENDOCRINOL},
	journal = {CLINICAL ENDOCRINOLOGY},
	unique-id = {34593007},
	issn = {0300-0664},
	abstract = {The adolescent period is characterised by fundamental hormonal changes, which affect sex steroid production, cortisol metabolism and insulin sensitivity. These physiological changes have a significant impact on patients with congenital adrenal hyperplasia (CAH). An essential treatment aim across the lifespan in patients with CAH is to replace glucocorticoids sufficiently to avoid excess adrenal androgen production but equally to avoid cardiometabolic risks associated with excess glucocorticoid intake. The changes to the hormonal milieu at puberty, combined with poor adherence to medical therapy, often result in unsatisfactory control exacerbating androgen excess and increasing the risk of metabolic complications due to steroid over-replacement. With the physical and cognitive maturation of the adolescent with CAH, fertility issues and sexual function become a new focus of patient care in the paediatric clinic. This requires close surveillance for gonadal dysfunction, such as irregular periods/hirsutism or genital surgery-associated symptoms in girls and central hypogonadism or testicular adrenal rest tumours in boys. To ensure good health outcomes across the lifespan, the transition process from paediatric to adult care of patients with CAH must be planned carefully and early from the beginning of adolescence, spanning over many years into young adulthood. Its key aims are to empower the young person through education with full disclosure of their medical history, to ensure appropriate follow-up with experienced physicians and facilitate access to multispecialist teams addressing the complex needs of patients with CAH.},
	keywords = {CORTISOL; Androgens; puberty; 21-hydroxylase deficiency; glucocorticoid},
	year = {2023},
	eissn = {1365-2265},
	orcid-numbers = {Idkowiak, Jan/0000-0001-9181-3995}
}

@article{MTMT:34339797,
	title = {Creating a SNOMED CT reference set for common endocrine disorders based on routine clinic correspondence},
	url = {https://m2.mtmt.hu/api/publication/34339797},
	author = {Yap, Shao Hao Alan and Philip, Sam and Graveling, Alex J. and Abraham, Prakash and Downs, Denise},
	doi = {10.1111/cen.14951},
	journal-iso = {CLIN ENDOCRINOL},
	journal = {CLINICAL ENDOCRINOLOGY},
	unique-id = {34339797},
	issn = {0300-0664},
	abstract = {BackgroundRoutine clinical coding of clinical outcomes in outpatient consultations still lags behind the coding of episodes of inpatient care. Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) offers an opportunity for standardised coding of key clinical information. Identifying the most commonly required SNOMED terms and grouping these into a reference set will aid future adoption in routine clinical care. ObjectiveTo create a common endocrinology reference set to standardise the coding for outcomes of outpatient endocrine consultations, using a semi-automated extraction of information from existing clinical correspondence. MethodsRetrospective review of data from an adult tertiary outpatient endocrine clinic between 2018 and 2019. A total of 1870 patients from postcodes within two regional areas of NHS Grampian (Aberdeen City and Aberdeenshire) attended the clinic. Following consultation, an automated script extracted each problem statement which was manually coded using the 'disorder' concepts from SNOMED CT (UK edition). ResultsThe review identified 298 relevant endocrine diagnoses, 99 findings and 142 procedures. There were a total of 88 (29.5%) commonly seen endocrine conditions (e.g., Graves' disease, anterior hypopituitarism and Addison's disease) and 210 (70.5%) less commonly seen endocrine conditions. Subsequently, consultant endocrinologists completed a survey regarding the common endocrine conditions; 28 conditions have 100% agreement, 25 have 90%-99% agreement, 31 have 50%-89% agreement and 4 have less than 59% agreement (which were excluded). ConclusionAutomated text parsing of structured endocrine correspondence allowed the creation of a SNOMED CT reference set for common endocrine disorders. This will facilitate funding and planning of service provision in endocrinology by allowing more accurate characterisation of the patient cohorts needing specialist endocrine care.},
	keywords = {PITUITARY; ENDOCRINOLOGY; ONTOLOGY; Thyroid; SNOMED CT; Reference set; medical coding; clinical problem lists; outpatient consultation; Refset},
	year = {2023},
	eissn = {1365-2265},
	orcid-numbers = {Philip, Sam/0000-0001-6164-211X}
}

@article{MTMT:34280659,
	title = {Genetically predicted plasma cortisol and common chronic diseases: A Mendelian randomization study},
	url = {https://m2.mtmt.hu/api/publication/34280659},
	author = {Lee, Wei-Hsuan and Larsson, Susanna C. and Wood, Angela and Di Angelantonio, Emanuele and Butterworth, Adam S. and Burgess, Stephen and Allara, Elias},
	doi = {10.1111/cen.14966},
	journal-iso = {CLIN ENDOCRINOL},
	journal = {CLINICAL ENDOCRINOLOGY},
	unique-id = {34280659},
	issn = {0300-0664},
	abstract = {ObjectiveCushing's syndrome is characterized by hypercortisolaemia and is frequently accompanied by comorbidities such as type 2 diabetes, hypertension, osteoporosis, depression and schizophrenia. It is unclear whether moderate but lifelong hypercortisolaemia is causally associated with these diseases in the general population. We aimed to address this research gap using a Mendelian randomization approach.MethodsWe used three cortisol-associated genetic variants in the SERPINA6/SERPINA1 region as genetic instruments in a two-sample, inverse-variance-weighted Mendelian randomization analysis. We obtained summary-level statistics for cortisol and disease outcomes from publicly available genetic consortia, and meta-analysed them as appropriate. We conducted a multivariable Mendelian randomization analysis to assess potential mediating effects.ResultsA 1 standard deviation higher genetically predicted plasma cortisol was associated with greater odds of hypertension (odds ratio: 1.12; 95% confidence interval [CI]: 1.05-1.18) as well as higher systolic blood pressure (mean difference [MD]: 0.03 SD change; 95% CI: 0.01-0.05) and diastolic blood pressure (MD: 0.03 SD change; 95% CI: 0.01-0.04). There was no evidence of association with type 2 diabetes, osteoporosis, depression and schizophrenia. The association with hypertension was attenuated upon adjustment for waist circumference, suggesting potential mediation through central obesity.ConclusionThere is strong evidence for a causal association between plasma cortisol and greater risk for hypertension, potentially mediated by obesity.},
	keywords = {HYPERTENSION; CORTISOL; osteoporosis; Type 2 diabetes; Mendelian randomization; chronic diseases; major mental illness},
	year = {2023},
	eissn = {1365-2265}
}

@article{MTMT:34273577,
	title = {Paediatric phaeochromocytoma and paraganglioma: A clinical update},
	url = {https://m2.mtmt.hu/api/publication/34273577},
	author = {Nazari, Matthew A. and Jha, Abhishek and Kuo, Mickey J. M. and Patel, Mayank and Prodanov, Tamara and Rosenblum, Jared S. and Talvacchio, Sara and Derkyi, Alberta and Charles, Kailah and Pacak, Karel},
	doi = {10.1111/cen.14955},
	journal-iso = {CLIN ENDOCRINOL},
	journal = {CLINICAL ENDOCRINOLOGY},
	unique-id = {34273577},
	issn = {0300-0664},
	abstract = {Paediatric phaeochromocytomas and paragangliomas (PPGLs), though rare tumours, are associated with significant disability and death in the most vulnerable of patients early in their lives. However, unlike cryptogenic and insidious disease states, the clinical presentation of paediatric patients with PPGLs can be rather overt, allowing early diagnosis, granted that salient findings are recognized. Additionally, with prompt and effective intervention, prognosis is favourable if timely intervention is implemented. For this reason, this review focuses on four exemplary paediatric cases, succinctly emphasizing the now state-of-the-art concepts in paediatric PPGL management.},
	keywords = {GENETICS; pathology; paediatric; Molecular imaging; Disease Management; Phaeochromocytoma; Paraganglioma},
	year = {2023},
	eissn = {1365-2265}
}

@article{MTMT:34259497,
	title = {Number of CAG repeats and mortality in middle aged and older men},
	url = {https://m2.mtmt.hu/api/publication/34259497},
	author = {Heald, Adrian and Cook, Michael J. and Antonio, Leen and Tournoy, Jos and Ghaffari, Parisa and Mannan, Fahmida and Fachim, Helene and Vanderschueren, Dirk and Laing, Ian and Hackett, Geoff and Casanueva, Felipe F. and Huhtaniemi, Ilpo T. and Maggi, Mario and Rastrelli, Giulia and Slowikowska-Hilczer, Jolanta and Wu, Fred and O'Neill, Terence W.},
	doi = {10.1111/cen.14962},
	journal-iso = {CLIN ENDOCRINOL},
	journal = {CLINICAL ENDOCRINOLOGY},
	unique-id = {34259497},
	issn = {0300-0664},
	abstract = {Design: The androgen receptor (AR) mediates peripheral effects of testosterone. Previous data suggests an association between the number of CAG repeats in exon-1 of the AR gene and AR transcriptional activity. The aim of this analysis was to determine the association between the number of AR CAG repeats and all-cause mortality in men and the influence of testosterone level on the association.Patients and Measurements: Follow-up data to 27 January 2018 were available for men aged 40-79 years recruited across six countries of the European Male Aging Study between 2003 and 2005. Cox proportional hazards modelling was used to determine the association between CAG repeat number/mortality. Results were expressed as hazard ratios (HR)/95% confidence intervals (CI).Results: One thousand nine hundred and seventy-seven men were followed up. Mean baseline age was 60 +/- 11.1 years. Mean duration of follow-up was 12.2 years. At follow up 25.1% of men had died. CAG repeat length ranged from 6 to 39, with the highest proportion of CAG repeat number at 21 repeats (16.4%). In a multivariable model, compared to men with 22-23 AR CAG repeats: for men with <22 and > 23 AR CAG HR, 95% CI for mortality were, <22 CAG repeats 1.17 (0.93-1.49) and >23 CAG repeats 1.14 (0.88-1.47). In a post-hoc analysis, the association was significant for men in the lowest tertile of baseline testosterone (<14.2 nmol/L) with >23 CAG repeats: in the adjusted model for <22 and > 23 CAG repeats, respectively, 1.49 (0.97-2.27) and 1.68 (1.06- 2.67) versus 22- 23 repeats.Conclusions: Our European-wide cohort data overall found no association of androgen receptor CAG repeat number and mortality in men. However, post hoc analysis suggested that an association might be present in men with lower baseline testosterone concentrations, which merits further investigation.},
	keywords = {Male; MORTALITY; testosterone; EMAS; CAG},
	year = {2023},
	eissn = {1365-2265},
	orcid-numbers = {Antonio, Leen/0000-0002-1079-2860}
}

@article{MTMT:34259467,
	title = {The biochemical confirmation of adult male hypogonadism: Global perspectives from the International Society of Andrology},
	url = {https://m2.mtmt.hu/api/publication/34259467},
	author = {Corona, Giovani and Goulis, Dimitrios. G. G. and Liu, Peter. Y. Y.},
	doi = {10.1111/cen.14941},
	journal-iso = {CLIN ENDOCRINOL},
	journal = {CLINICAL ENDOCRINOLOGY},
	unique-id = {34259467},
	issn = {0300-0664},
	keywords = {testosterone; GUIDELINES; andrology},
	year = {2023},
	eissn = {1365-2265}
}

@article{MTMT:34259462,
	title = {Standardising the biochemical confirmation of adult male hypogonadism: A joint position statement by the Society for Endocrinology and Association of Clinical Biochemistry and Laboratory Medicine},
	url = {https://m2.mtmt.hu/api/publication/34259462},
	author = {Jayasena, Channa N. and de Silva, Nipun L. and O'Reilly, Michael W. and MacKenzie, Finlay and Marrington, Rachel and Jones, Hugh and Livingston, Mark and Downie, Paul and Hackett, Geoff and Ramachandran, Sud and Tomlinson, Jeremy and David, Janine and Boot, Christopher and Patel, Mayur and Tarling, Julie and Wu, Fredrick and Quinton, Richard},
	doi = {10.1111/cen.14929},
	journal-iso = {CLIN ENDOCRINOL},
	journal = {CLINICAL ENDOCRINOLOGY},
	unique-id = {34259462},
	issn = {0300-0664},
	abstract = {BackgroundInter-assay variation between different immunoassays and different mass spectrometry methods hampers the biochemical confirmation of male hypogonadism. Furthermore, some laboratories utilise assay manufacturer reference ranges that do not necessarily mirror assay performance characteristics, with the lower limit of normality ranging from 4.9 nmol/L to 11 nmol/L. The quality of the normative data underlying commercial immunoassay reference ranges is uncertain. DesignA working group reviewed published evidence and agreed upon standardised reporting guidance to augment total testosterone reports. ResultsEvidence-based guidance on appropriate blood sampling, clinical action limits, and other major factors likely to affect the interpretation of results are provided. ConclusionsThis article aims to improve the quality of the interpretation of testosterone results by non-specialist clinicians. It also discusses approaches for assay harmonisation which have been successful in some but not all healthcare systems.},
	keywords = {ASSAY; testosterone; male hypogonadism},
	year = {2023},
	eissn = {1365-2265}
}

@article{MTMT:34259455,
	title = {Men, testosterone and Covid-19},
	url = {https://m2.mtmt.hu/api/publication/34259455},
	author = {Antonic, Kristina Groti and Antonic, Blaz and Caliber, Monica and Dhindsa, Sandeep},
	doi = {10.1111/cen.14952},
	journal-iso = {CLIN ENDOCRINOL},
	journal = {CLINICAL ENDOCRINOLOGY},
	unique-id = {34259455},
	issn = {0300-0664},
	abstract = {Men have more severe Coronavirus disease 2019 (Covid-19) outcomes and higher mortality rates than women, and it was suggested that testosterone levels might promote severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and Covid-19 severity. However, clinical studies have not supported this theory. Studies have consistently shown that serum testosterone concentrations during acute Covid-19 in men are inversely proportional to the inflammatory cytokines and severity of illness. It is likely that lower testosterone concentrations in this setting are a result of acute Covid-19 illness on the hypothalamic-pituitary-testicular axis. Clinical trials that attempted to lower testosterone concentrations further or block androgen signaling acutely during Covid-19 in men did not result in improved Covid-19 outcomes. Additionally, pre-existing male hypogonadism, diagnosed before Covid-19 pandemic, was found to be a risk factor for hospitalization from Covid-19. In this review, we also discuss the preclinical and mechanistic studies that have evaluated the role of androgens in SARS-CoV-2 infection and illness. Finally, long-term consequences of Covid-19 on male reproductive health are reviewed. SARS-CoV-2 virus is known to infiltrate testis and induce orchitis in men, but it is unclear if Covid-19 leads to an increase in incidence of male hypogonadism.},
	keywords = {TESTES; testosterone; hypogonadism; COVID-19; SARS-CoV-2},
	year = {2023},
	eissn = {1365-2265},
	orcid-numbers = {Antonic, Kristina Groti/0000-0002-4078-0238}
}